Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P399: Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Steen*1, M. McCormack2, C. McShane1, M. Healy2, V. Crowley2, U. Kennedy1, O. Hayes1, C. Dunne1, K. Hartery1, S. McKiernan1, F. MacCarthy1, D. Kevans1

1St. James Hospital, Gastroenterology, Dublin, Ireland, 2St. James Hospital, Biochemistry, Dublin, Ireland

P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Peyrin-Biroulet1, A. Hart2, C. Kayhan3, A. Armuzzi4, S. Schreiber*5

1Nancy University Hospital, Lorraine University, Vandœuvre-lès-Nancy, France, 2St. Mark’s Hospital, IBD Unit, London, UK, 3Pfizer Inc., Collegeville, PA, USA, 4Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, IBD Unit, Rome, Italy, 5University Hospital Schleswig-Holstein, Department of Internal Medicine, Kiel, Germany

P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. O'Connell1, M. S. Ismail2, M. McCormack3, P. McDonagh1, R. Argue4, N. Breslin2,5, V. Crowley3, G. Cullen5,6, G. A. Doherty5,6, C. Dunne1,5, K. Hartery1,5, F. MacCarthy5,7, S. McKiernan1,5, H. Mulcahy5,6, A. O'Connor2,5, C. O'Morain8, B. Ryan2,5, J. Sheridan5,6, M. Healy3, D. McNamara2,5, D. Kevans1,5

1St James's Hospital, Department of Gastroenterology, Dublin, Ireland, 2Tallaght University Hospital, Department of Gastroenterology, Dublin, Ireland, 3St James's Hospital, Department of Biochemistry, Dublin, Ireland, 4Trinty College Dublin, School of Medicine, Dublin, Ireland, 5INITIative, Investigator Network Inflammatory bowel disease Therapy in Ireland, Dublin, Ireland, 6St Vincent's University Hospital, Gastroenterology, Dublin, Ireland, 7St James's Hospital, Gastroenterology, Dublin, Ireland, 8Beacon Hospital, Gastroenterology, Dublin, Ireland

P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Timeus1, R. Hofmann*2

1Tillotts Pharma AG, Drug Safety, Rheinfelden, Switzerland, 2Tillotts Pharma AG, Medicines Management, Rheinfelden, Switzerland

P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Ranjan*1, D. Rayner1, F. Maw1, A. Dhar1

1County Durham and Darlington NHS Foundation Trust, Gastroenterology, Durham, UK

P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Ungaro*1, B. Limketkai2, C. B. Jensen3, C. Yzet4, K. H. Allin3, M. Agrawal5, J. Burisch3, T. Ullman6, T. Jess3, J-F. Colombel1

1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, USA, 3Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 4Amiens University Hospital, Amiens, France, 5Division of Gastroenterology and Hepatology, Lenox Hill Hospital, New York, USA, 6Division of Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, USA

P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Doherty*1, M. Buckley1, G. Cullen1, D. Keegan1, K. Byrne1, G. Horgan1, H. Mulcahy1, J. Sheridan1, G. A. Doherty1,2

1Centre for Colorectal Disease, St Vincent’s University Hospital and School of Medicine, University College Dublin, Gastroentrology, Dublin, Ireland, 2UCD Clinical Professor, School of Medicine, University College Dublin, School of Medicine, University College Dublin, Dublin, Ireland

P406: General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese*1, B. E. Sands2, R. W. Leong3,4, H. Zhang5, J. Johanns5, P. Szapary5, C. Marano5, C. Han6

1Humanitas Research Hospital, Milan, Italy, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Concord Hospital, Sydney, Australia, 4Macquarie University Hospital, Sydney, Australia, 5Janssen Research and Development, LLC, Spring House, USA, 6Janssen Global Services, LLC, Malvern, USA

P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Yarur*1, L. Bixuan1, P. Deepak2, A. Khatiwada2, G. Christophi2, M. Ciorba2, R. Ungaro3, M. Fenster3, C. Dimopoulos3, G. Syal4, R. Hirten3, J-F. Colombel3, C. Ha4, R. Weisshof5, J. Pekow5, A. Patel6, P. Beniwal-Patel1, B. Cohen3

1Medical College of Wisconsin, Gastroenterology, Milwaukee, USA, 2Washington University in St Louis School of Medicine, Gastroenterology, Saint Louis, USA, 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, USA, 4CedarsSinai Medical Center, Gastroenterology, Los Angeles, USA, 5University of Chicago, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, USA, 6Brooke Army Medical Center, Gastroenterology, Fort Sam Houston, USA

P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. van Hoeve*1,2, E. Dreesen3, I. Hoffman1, M. Ferrante2,4, A. Gils3, S. Vermeire2,4

1University Hospitals Leuven, Department of Paediatric gastroenterology and Hepatology and Nutrition, Leuven, Belgium, 2Catholic University of Leuven (KU Leuven), TARGID, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 3Catholic University of Leuven (KU Leuven), Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 4University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Gonczi*1, A. Ilias1, K. Szanto2, Z. Kurti1, P. A. Golovics3, K. Farkas2, E. Schafer3, Z. Szepes2, B. Szalay4, A. Vincze5, T. Szamosi3, T. Molnar2, P. Lakatos6

1Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Military Hospital – State Health Centre, Department of Gastroenterology, Budapest, Hungary, 4Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, 5University of Pecs, First Department of Medicine, Pecs, Hungary, 6McGill University Health Center, Division of Gastroenterology, Montreal, Canada

P410: Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ghosh*1, F. Casellas2, C. O’Shea3, M. Leonard3, J. Petersson4, L. Peyrin-Biroulet5

1University of Birmingham, Birmingham, UK, 2Crohn-Colitis Care Unit (UACC), Hospital Universitari Vall, Vall d'Hebron, Spain, 3AbbVie Ltd., Dublin, Ireland, 4AbbVie Inc., North Chicago, Illinois, USA, 5University of Lorraine, Nancy, France

P411: Using wearable devices to assess pain in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

O. V. Yvellez*1, P. H. Sossenheimer1, M. Andersen Jr1, K. El Jurdi1, A. Mayampurath2, D. T. Rubin1

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, USA, 2Litmus Health, Inc., Austin, TX, USA

P412: Efficacy and safety of additional autologous platelet-rich stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Arkenbosch*1, O. van Ruler2, W. Deijl2, J. Stevens3, A. de Vries4, J. van der Woude4, E. de Graaf2, R. Schouten1,2

1Erasmus Medical Center, Department Colorectal surgery, Rotterdam, The Netherlands, 2Ijsselland Hospital, Department Colorectal surgery, Capelle a/d Ijssel, The Netherlands, 3Bergman Clinics, Department Reconstructive surgery, Bilthoven, The Netherlands, 4Erasmus Medical Center, Department Gastroenterology, Rotterdam, The Netherlands

P413: A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

P. S. Dulai*1, A. Amiot2, L. Peyrin-Biroulet3, S. Singh1, M. Serrero4, V. Jairath5, J. Filippi6, B. Pariente7, E. V. Loftus Jr8, X. Roblin9, S. Kane8, A. Buisson10, C. A. Siegel11, Y. Bouhnik12, W. J. Sandborn1, K. Lasch13, M. Rosario13, B. G. Feagan5, D. Bojic14, C. Trang-Poisson15, B. Shen16, R. Altwegg17, B. E. Sands18, J-F. Colombel18, F. Carbonnel19, M. Bohm20, D. Hudesman21, A. Bourrier22, D. Lukin23, GETAID OBSERV-IBD and VICTORY Cohorts Collaboration1

1University of California San Diego, La Jolla, CA, USA, 2Henri Mondor University Hospital, Creteil, France, 3University of Lorraine, Nancy, France, 4Aix-Marseille University, Marseille, France, 5University of Western Ontario, London, ON, Canada, 6Nice University Hospital, Nice, France, 7Claude Huriez Hospital, Lille, France, 8Mayo Clinic, Rochester, MN, USA, 9University Hospital of Saint-Etienne, Saint-Etienne, France, 10Estaing University Hospital, Clermont-Ferrand, France, 11Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 12Beaujon Hospital, Clichy, France, 13Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA, 14Takeda Pharmaceuticals International AG, Zurich, Switzerland, 15University Hospital of Nantes, Nantes, France, 16Cleveland Clinic Foundation, Cleveland, OH, USA, 17University Hospital of Montpellier Saint-Eloi, Montpellier, France, 18Icahn School of Medicine at Mount Sinai, New York, NY, USA, 19Bicetre University Hospital, Paris, France, 20Indiana University, Indianapolis, IN, USA, 21New York University (NYU), New York, NY, USA, 22Saint-Antoine University Hospital, Paris, France, 23Montefiore Medical Center, New York, NY, USA

P414: Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction

ECCO '19 Copenhagen

Year: 2019
Authors:

R. W. M. Pauwels*1, A. C. de Vries1, J. C. Goet1, N. S. Erler2, C. J. van der Woude1

1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands

P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Rivière1, A. Malian1, D. Bouchard2, F. Pigot2, M. Eleouet-Kaplan2, C. Favreau-Weltzer2, F. Poullenot1, D. Laharie1

1Bordeaux University Hospital, Gastroenterology and nutrition, Bordeaux, France, 2Bagatelle Health Center, Proctology, Bordeaux, France

P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Bertani*1, L. Ceccarelli2, M. G. Mumolo2, R. Tedeschi1, E. Albano1, G. Tapete1, G. Baiano Svizzero1, N. De Bortoli1, A. Ricchiuti2, M. Bellini1, S. Marchi1, F. Costa2

1University of Pisa, Department of New Technologies and Translational Sciences in Medicine And Surgery, Pisa, Italy, 2Pisa University Hospital, Department of General Surgery and Gastroenterology, Pisa, Italy

P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Aichinger1, K. Rothfuss1, M. Koch1, E. F. Stange1, J. G. Albert1, C. Schäfer1

1Robert Bosch Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Stuttgart, Germany

P418: Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Higgins*1, D. Ginsburg2, K. Gilder3, K. Gilder3, B. Walsh3, B. English3, S. Turner3, P. Klassen3, S. Hanauer4, C. Barish5, B. Yacyshyn6

1University of Michigan, Internal Medicine, Ann Arbor, USA, 2Multicare Institute, Tacoma, USA, 3Arena Pharmaceuticals, San Diego, USA, 4Northwestern University, Chicago, USA, 5University of North Carolina, Chapel Hill, USA, 6University of Cincinnati, Cincinnati, USA